Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

UK Health Body Approves Novartis's Tasigna For CML

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2012 | 01:16am CEST

The U.K.'s health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from U.S.-based Bristol-Myers Squibb Co. (BMY)--after the Swiss drug maker offered to cut the drug's price.

The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it approved Novartis's Tasigna and the company's older drug, whose brand name is Glivec, for use in treating CML on the publicly funded National Health Service. The generic names for Tasigna and Glivec are nilotinib and imatinib, respectively.

However, NICE said it wasn't approving Bristol-Myers Squibb's Sprycel, also known as dasatinib.

CML is a cancer of blood-forming cells in the bone marrow that usually develops slowly, which is why it is described as a chronic form of the disease.

NICE director Carole Longson said: "The recommendations reaffirm the use of imatinib as an effective treatment for the majority of patients and a cost-effective use of NHS resources, and we are also very pleased to be able to add a further treatment option for these patients by recommending nilotinib.

"Although no trials directly comparing dasatinib and nilotinib were available, the committee concluded from indirect comparisons that dasatinib and nilotinib could be considered equally as effective in treating CML.

"However, the manufacturer of nilotinib has already agreed with the Department of Health to provide the drug to the NHS at a discounted price. This reduction in cost enabled the independent committee to approve nilotinib for use on the NHS."

Dasatinib and nilotinib both cost over GBP30,000 per patient a year and the standard dose of imatinib costs GBP20,000.

NICE didn't disclose the price discount offered by Novartis for nilotinib.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS AG
07:16a NOVARTIS : ' new analyses reinforce the potential of Ultibro® Breezhaler® for CO..
05/19 NOVARTIS : receives positive CHMP opinion for first-line use of Zykadia® in ALK-..
05/18 NOVARTIS : receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack ..
05/18 NOVARTIS : Researchers Submit Patent Application, "Methods of Treating Anorexia"..
05/18 DURECT : and Sandoz have Signed a $293 Million Development and Commercialization..
05/18 NOVARTIS : to cut around 500 jobs in Switzerland, add 350
05/18 NOVARTIS : data at ASCO, ICML and EHA meetings demonstrate meaningful advancemen..
05/17 NOVARTIS : Combine Solicitation - Alcon Phaco Cartridges
05/17 NOVARTIS : Foundation and partners launch initiative to tackle hypertension and ..
05/17 NOVARTIS : Higginbotham, Alcon nominated for Texas Enterprise Zone projects by F..
More news
Sector news : Pharmaceuticals - NEC
12:32p UK competition watchdog accuses Merck of obstructing biosimilars
08:35aDJASTRAZENECA : Says Bydureon Trial Meets Safety Objectives; No Significant CV Red..
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJASTRAZENECA : in Pact with Recordati for Heart-Drug Seloken in Europe
05/19 European shares claw back gains after worst week in six months
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/22 Tracking Tweedy Browne Portfolio - Q1 2017 Update
05/20 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 20, 2017
05/19 Asco Preview - Breast Cancer And I-O Combos Grab The Early Headlines
05/19 European Ad Comm backs expanded use of Novartis' Zykadia
05/18 NOVARTIS : Follow The (Belgian) Yellow Brick Road
Advertisement
Financials ($)
Sales 2017 48 338 M
EBIT 2017 11 983 M
Net income 2017 7 480 M
Debt 2017 14 035 M
Yield 2017 3,47%
P/E ratio 2017 24,81
P/E ratio 2018 21,99
EV / Sales 2017 4,71x
EV / Sales 2018 4,51x
Capitalization 213 719 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 31
Average target price 80,0 $
Spread / Average Target -1,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG6.28%213 719
JOHNSON & JOHNSON10.23%342 817
ROCHE HOLDING LTD.14.79%237 610
PFIZER INC.-1.11%191 279
MERCK & CO., INC.8.78%175 160
SANOFI14.93%124 306
More Results